Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Apellis Pharmaceuticals, Inc. < Previous 1 2 Next > Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results October 25, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA) October 20, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week October 17, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 05, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023 October 05, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration October 02, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023 September 25, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 06, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Present at Upcoming Investor Conferences September 05, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Present at Upcoming Investor Conferences August 30, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success August 29, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection) August 22, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 04, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results July 31, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA) July 30, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy July 29, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results July 24, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting July 10, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 06, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference June 07, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 06, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS May 25, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 05, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results May 04, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference May 03, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results April 27, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy April 23, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy April 21, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign April 17, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 06, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.